ABSI is trading 5% up now at $11.67 as the stock extends its recent AI-driven run, following sharp gains since late June tied to optimism around its AI-enabled drug discovery platform and bullish analyst sentiment. With no fresh company-specific headlines this morning, the move appears to be a continuation of that momentum, helped by a broadly positive U.S. market backdrop, where major indices are all trading higher.